Scientists have successfully engineered the most complicated human cell lines ever indicating that our genomes are more tolerant to significant structural alte ...

Learn more about whether Catalyst Pharmaceuticals, Inc. or CRISPR Therapeutics AG is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

January 31, 2025 expert reaction to NICE final draft guidance on exagamglogene autotemcel (exa-cel) for severe sickle cell disease . Scientists comment on final draft guidance fro ...

Read about exa-cel being rolled out on the NHS, providing a 'functional cure' for some patients with severe sickle cell ...

The most complex engineering of human cell lines ever has been achieved by scientists, revealing that our genomes are more resilient to significant structural changes than was previously thought.

The National Institute for Health and Care Excellence (NICE) has approved Vertex Pharmaceuticals’ Casgevy (exagamglogene ...

Scientists in China have created mice with two biological fathers, a milestone that challenges our understanding of mammalian ...

The Exa-cel gene therapy treatment is at the forefront of medical technology. It takes the person’s DNA and “edits” out the faulty sickle gene. It’s expensive, too. According to the manufacturer, ...

Learn more about whether Legend Biotech Corporation or Twist Bioscience Corporation is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.